GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cambium Bio Ltd (ASX:CMB) » Definitions » Cash Flow from Financing

Cambium Bio (ASX:CMB) Cash Flow from Financing : A$-0.40 Mil (TTM As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Cambium Bio Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Dec. 2023, Cambium Bio paid A$0.00 Mil more to buy back shares than it received from issuing new shares. It spent A$0.35 Mil paying down its debt. It paid A$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received A$0.00 Mil from paying cash dividends to shareholders. It received A$0.00 Mil on other financial activities. In all, Cambium Bio spent A$0.35 Mil on financial activities for the six months ended in Dec. 2023.


Cambium Bio Cash Flow from Financing Historical Data

The historical data trend for Cambium Bio's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cambium Bio Cash Flow from Financing Chart

Cambium Bio Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.63 0.40 -0.10 0.92 3.13

Cambium Bio Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.97 -0.05 -0.35 -

Cambium Bio Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Cambium Bio's Cash from Financing for the fiscal year that ended in Jun. 2024 is calculated as:

Cambium Bio's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cambium Bio  (ASX:CMB) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Cambium Bio's issuance of stock for the six months ended in Dec. 2023 was A$0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Cambium Bio's repurchase of stock for the six months ended in Dec. 2023 was A$0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Cambium Bio's net issuance of debt for the six months ended in Dec. 2023 was A$-0.35 Mil. Cambium Bio spent A$0.35 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Cambium Bio's net issuance of preferred for the six months ended in Dec. 2023 was A$0.00 Mil. Cambium Bio paid A$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cambium Bio's cash flow for dividends for the six months ended in Dec. 2023 was A$0.00 Mil. Cambium Bio received A$0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Cambium Bio's other financing for the six months ended in Dec. 2023 was A$0.00 Mil. Cambium Bio received A$0.00 Mil on other financial activities.


Cambium Bio Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Cambium Bio's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Cambium Bio Business Description

Traded in Other Exchanges
N/A
Address
16 Goodhope Street, Paddington, Sydney, NSW, AUS, 2021
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate Elate Ocular is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.

Cambium Bio Headlines

No Headlines